Baseline demographics and clinical characteristics (full analysis set)
| Characteristic | Current smoker# | Ex-smoker¶ | ||
| IND/GLY 110/50 µg once daily | SFC 50/500 µg twice daily | IND/GLY 110/50 µg once daily | SFC 50/500 µg twice daily | |
| Subjects n | 879 | 890 | 1427 | 1421 |
| Age years | 62.1±7.51 | 62.0±7.07 | 66.0±7.80 | 66.0±7.76 |
| Male | 643 (73.2) | 638 (71.7) | 1175 (82.3) | 1136 (79.9) |
| BMI kg·m−2 | 25.0±5.00 | 25.1±5.24 | 26.0±5.07 | 26.1±4.95 |
| Estimated number of pack-years | 43.0±18.51 | 44.4±21.88 | 39.6±22.58 | 39.3±22.00 |
| Duration of COPD years | 6.0±4.75 | 6.3±5.13 | 7.2±5.54 | 7.4±5.60 |
| Blood eosinophil count at baseline cells·µL−1 | 205.4±141.32 | 205.9±160.36 | 209.5±156.47 | 207.1±166.62 |
| Severity of airflow limitation, GOLD 2019 [25] | ||||
| Mild, GOLD 1 | 2 (0.2) | 1 (0.1) | ||
| Moderate, GOLD 2 | 386 (43.8) | 397 (44.6) | 573 (40.2) | 573 (40.3) |
| Severe, GOLD 3 | 437 (49.6) | 442 (49.6) | 761 (53.3) | 758 (53.3) |
| Very severe, GOLD 4 | 47 (5.3) | 44 (4.9) | 85 (6.0) | 80 (5.6) |
| Missing | 9 (1.0) | 7 (0.8) | 8 (0.6) | 11 (0.8) |
| Treatments at baseline+ | ||||
| LABA | 430 (48.8) | 453 (50.8) | 698 (48.9) | 674 (47.5) |
| LAMA | 393 (44.6) | 415 (46.6) | 613 (43.0) | 612 (43.0) |
| ICS | 442 (50.2) | 448 (50.3) | 826 (57.9) | 802 (56.4) |
| LABA/ICS | 283 (32.1) | 295 (33.1) | 501 (35.1) | 483 (34.0) |
| COPD exacerbation history | ||||
| 0 | 209 (23.7) | 200 (22.4) | 361 (25.3) | 340 (23.9) |
| 1 | 549 (62.3) | 570 (64.0) | 863 (60.5) | 878 (61.7) |
| ≥2 | 123 (14.0) | 120 (13.5) | 203 (14.2) | 204 (14.3) |
Data are presented as mean±sd or n (%), unless otherwise stated. IND/GLY: indacaterol/glycopyrronium; SFC: salmeterol/fluticasone; BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid. #: N=1769; ¶: N=2848; +: patients might be on more than one COPD therapy at baseline.